Skip Ribbon Commands
Skip to main content

Publications

List of Publications

Clinical
​1​Cost-Effectiveness Analysis of Liver Resection Versus Transplantation for Early Hepatocellular Carcinoma within the Milan Criteria. Lim, K. C., V. W. Wang, F. J. Siddiqui, L. M. Shi, S. Y. Chan, H. C. Oh, S. B. Tan, and P. K. Chow. Hepatology, (2014) 10.1002/hep.27135.
​2​Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma . Chow, Pierce K. H., Donald Y. H. Poon, Maung-Win Khin, Harjit Singh, Ho-Seong Han, Anthony S. W. Goh, Su-Pin Choo, Hee-Kit Lai, Richard H. G. Lo, Kiang-Hiong Tay, Teong-Guan Lim, Mihir Gandhi, Say-Beng Tan, Khee-Chee Soo, and Group for the Asia-Pacific Hepatocellular Carcinoma Trials. PLoS ONE 9, no. 3 (2014): e90909.
​3​Survival and Pattern of Tumor Progression with Yttrium-90 Microsphere Radioembolization in Predominantly Hepatitis B Asian Patients with Hepatocellular Carcinoma . Khor, AndrewYu-Keat, Ying Toh, JohnCarson Allen, DavidChee-Eng Ng, Yung-Hsiang Kao, Guili Zhu, Su-Pin Choo, RichardHoau-Gong Lo, Kiang-Hiong Tay, Jin-Yao Teo, BrianKim-Poh Goh, MarkChristiaan Burgmans, FarahGillian Irani, AnthonySoon-Whatt Goh, and PierceKah-Hoe Chow. Hepatology International, (2014): 1936-0541
​4​Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. Lau, W. Y., B. Sangro, P. J. Chen, S. Q. Cheng, P. Chow, R. C. Lee, T. Leung, K. H. Han, and R. T. Poon. Oncology 84, no. 5 (2013): 311-8.
​5​Systematic Review of Outcomes of Liver Resection for Early Hepatocellular Carcinoma within the Milan Criteria. Lim, K. C., P. K. Chow, J. C. Allen, F. J. Siddiqui, E. S. Chan, and S. B. Tan. Br J Surg 99, no. 12 (2012): 1622-9.
​6Activity of Thalidomide and Capecitabine in Patients with Advanced Hepatocellular Carcinoma. SF Ang, SH Tan, HC Toh, DYH Poon, SYK Ong, KF Foo , SP Choo Am J Clin Oncol 2011, Mar2 ( in press) [IF 2.206]
​7​Microvascular Invasion Is a Better Predictor of Tumor Recurrence and Overall Survival Following Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria . Lim, K. C., P. K. Chow, J. C. Allen, G. S. Chia, M. Lim, P. C. Cheow, A. Y. Chung, L. L. Ooi, and S. B. Tan. Ann Surg 254, no. 1 (2011): 108-13.]
​8​Randomised Double-Blind Trial of Megestrol Acetate Vs Placebo in Treatment-Naive Advanced Hepatocellular Carcinoma. Chow, P. K., D. Machin, Y. Chen, X. Zhang, K. M. Win, H. H. Hoang, B. D. Nguyen, M. Y. Jin, R. Lobo, M. Findlay, C. H. Lim, S. B. Tan, M. Gandhi, and K. C. Soo. Br J Cancer 105, no. 7 (2011): 945-52.
​9​A Novel Approach to Brachytherapy in Hepatocellular Carcinoma Using a Phosphorous32 (32p) Brachytherapy Delivery Device—a First-in-Man Study . Goh, Anthony Soon-Whatt, Alexander Yaw-Fui Chung, Richard Houa-Gong Lo, Te-Neng Lau, Sidney Wing-Kwong Yu, May Chng, Somanesan Satchithanantham, Susan Li-Er Loong, David Chee-Eng Ng, Beng-Choo Lim, Stephen Connor, and Pierce Kah-Hoe Chow. International journal of radiation oncology, biology, physics 67, no. 3 (2007): 786-792.
​10High-Dose Tamoxifen in the Treatment of Inoperable Hepatocellular Carcinoma: A Multicenter Randomized Controlled Trial. Chow, P. K., B. C. Tai, C. K. Tan, D. Machin, K. M. Win, P. J. Johnson, and K. C. Soo. Hepatology 36, no. 5 (2002): 1221-6.


Translational
​1​Deep Sequencing of the Hepatitis B Virus in Hepatocellular Carcinoma Patients Reveals Enriched Integration Events, Structural Alterations and Sequence Variations. Toh, S. T., Y. Jin, L. Liu, J. Wang, F. Babrzadeh, B. Gharizadeh, M. Ronaghi, H. C. Toh, P. K. Chow, A. Y. Chung, L. L. Ooi, and C. G. Lee. Carcinogenesis 34, no. 4 (2013): 787-98. 
​2​Altered Binding Site Selection of P53 Transcription Cassettes by Hepatitis B Virus X Protein. Chan, C., Y. Wang, P. K. Chow, A. Y. Chung, L. L. Ooi, and C. G. Lee. Mol Cell Biol 33, no. 3 (2013): 485-97.
​3​Microrna-224 Is up-Regulated in Hepatocellular Carcinoma through Epigenetic Mechanisms. Wang, Y., H. C. Toh, P. Chow, A. Y. Chung, D. J. Meyers, P. A. Cole, L. L. Ooi, and C. G. Lee. FASEB J 26, no. 7 (2012): 3032-41.
​4​Dovitinib demonstrates antitumor and antimetastatic activitiesin xenograft models of hepatocellular carcinoma. Huynh, H, P.K. Chow, W. M. Tai, S. P. Choo, A.Y.F.Chung, H.S.Ong, K.C.Soo, R.Ong, R.Linnartz, M.M.Shi. J Hepatol (2012) 56(3):595-601
​5​Azd6244 Enhances the Anti-Tumor Activity of Sorafenib in Ectopic and Orthotopic Models of Human Hepatocellular Carcinoma (HCC). Huynh, H., V. C. Ngo, H. N. Koong, D. Poon, S. P. Choo, H. C. Toh, C. H. Thng, P. Chow, H. S. Ong, A. Chung, B. C. Goh, P. D. Smith, and K. C. Soo. J Hepatol 52, no. 1 (2010): 79-87. [IF 7.818]
​6​Lethal-7 Is Down-Regulated by the Hepatitis B Virus X Protein and Targets Signal Transducer and Activator of Transcription 3. Wang, Y., Y. Lu, S. T. Toh, W. K. Sung, P. Tan, P. Chow, A. Y. Chung, L. L. Jooi, and C. G. Lee. J Hepatol 53, no. 1 (2010): 57-66. 
​7​Sorafenib and Rapamycin Induce Growth Suppression in Mouse Models of Hepatocellular Carcinoma. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo K.C J Cell Mol Med. 2009 Aug;13(8B):2673-83.[IF 6.807] 
​8​RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. Hung H, KH P Chow, KC Soo, HC Toh, SP Choo, KF Foo, DPoon, VC Ngo,E Tran. J Cell Mol Med. 2009;13(7):1371-80. [IF6.807]
​9Sunitinib (Sutent, Su11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma. Huynh, H., V. C. Ngo, S. P. Choo, D. Poon, H. N. Koong, C. H. Thng, H. C. Toh, L. Zheng, L. C. Ong, Y. Jin, I. C. Song, A. P. Chang, H. S. Ong, A. Y. Chung, P. K. Chow, and K. C. Soo. Curr Cancer Drug Targets 9, no. 6 (2009): 738-47. [IF 5.129]
​10​Effective Inhibition of Xenografts of Hepatocellular Carcinoma (Hepg2) by Rapamycin and Bevacizumab in an Intrahepatic Model. Ong, L. C., I. C. Song, Y. Jin, I. H. Kee, E. Siew, S. Yu, C. H. Thng, H. Huynh, and P. K. Chow. Mol Imaging Biol 11, no. 5 (2009): 334-42.